tranScrip Announces the Appointment of Dr Christopher Floyd as Executive Medical Director, Early Development

tranScrip is delighted to announce the appointment of Dr. Christopher Floyd as Executive Medical Director, Early Development.

In his new role, Christopher will enhance tranScrip’s senior expertise in translational medicine and clinical pharmacology. His appointment reinforces tranScrip’s commitment to enabling clients to maximise the value of their products for the benefit of patients worldwide.

With over a decade of experience in drug development, Christopher has provided medical oversight for numerous early-phase studies, expertly bridging translational science with clinical development plans. His background in indication evaluation, clinical strategy, and early product profile development—combined with his collaborative work with commercial, regulatory, and safety teams—makes him a valuable addition to our leadership.

Commenting on his appointment, Christopher stated: “I am delighted to join tranScrip and contribute to its continued growth and success. The company’s unique approach to delivering value throughout the entire product lifecycle inspires me, and I look forward to driving innovation in early development and advancing groundbreaking therapies for patients in need.”

Linda Summerton, Chief Scientific Officer at tranScrip, added: “We are thrilled to welcome Chris to our team as we expand our Early Development capabilities. His deep expertise in translational medicine and clinical pharmacology, alongside his proven leadership in cross-functional teams, will be instrumental as we further our commitment to expediting the development and commercialisation of vital treatments worldwide.”

Christopher’s impressive career began with training in General Internal Medicine and Clinical Pharmacology & Therapeutics, followed by an academic stint at King’s College London. Most recently, he served as Senior Director at GSK within the Respiratory and Immunology Research Unit, where he managed projects from target identification through to marketing authorisation applications. His interests in cardiovascular, nephrology, respiratory, and rare diseases are well supported by his extensive experience in both biopharmaceuticals and small molecules targeting a range of immunological and non-immunological mechanisms.

Christopher earned his medical degree from the University of Cambridge and University College London and was awarded a PhD from King’s College London. He is a member of the Royal College of Physicians and a fellow of the Higher Education Authority, the British Pharmacological Society, and the Faculty of Pharmaceutical Medicine.

This appointment further underscores tranScrip’s dedication to providing expert support across every stage of the product lifecycle – from TRANslation to preSCRIPtion.

For more insights into our team members, visit Our People.

About tranScrip
tranScrip is a highly specialist pharmaceutical consultancy providing strategic expertise, therapeutic experience and operational excellence across the entire product lifecycle – from TRANslation to preSCRIPtion. We exist to expedite the development and commercialisation of products for the benefit of patients worldwide. For more information, please visit www.transcrip-group.com and follow us on LinkedIn.

Media Contact
Ashton Brooke-Thorne
Senior Marketing Manager
ashton.brooke-thorne@transcrip-group.com